As shown in Table 4, these trials combine checkpoint inhibitors (anti-PD-1/PD-L1), kinase inhibitors, chemotherapeutic drugs, and endocrine therapy as they are targeted at patients with HR+ breast cancer. This evidence concerns the gene CD274 and breast cancer.